Valneva: positive three-year data for Ixchiq

(CercleFinance.com) - Valneva has announced positive data on antibody persistence three years after vaccination with a single dose of its Ixchiq, the world's first and only licensed chikungunya vaccine to address this unmet medical need.


The company says that these results, in line with the positive persistence data announced at twelve months and two years, confirm robust and durable antibody persistence in all vaccinated age groups.

Valneva thus points to a high seroresponse rate of 96%, in line with the data obtained at two years, as well as comparable long-term persistence of antibodies in older adults (over 65) and young adults.


Copyright (c) 2024 CercleFinance.com. All rights reserved.